Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any inaccuracies are welcome. This article is only an introduction to pharmaceuticals related to healthcare and is not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.
On the morning of December 8, 2023, the opening ceremony of Suzhou Olipharma Technology Co., Ltd.'s oligonucleotide drug CDMO platform was successfully held at Phase I of WuZhong Biomedical Industry Park LifeBay.
The opening ceremony was hosted by Dr. Wang Yunduan, Vice General Manager of Olipharma. Government leaders attending the event included Gu Hongjian, member of the Working Committee of Wu Zhong Economic Development Zone and Deputy Director of the Management Committee; Li Ji, Director of the Investment Promotion Bureau of Wu Zhong Economic Development Zone; and Tong Tong, Chairman of Wu Zhong Biopharmaceutical Industry Development Co., Ltd. Additionally, Sun Linghao, Managing Director of Matrix Partners, a investor in Olipharma; Li Jing, Vice President of Clearpine Capital; Zhang Lu, Partner of Yidai Capital; Zhao Hai, Founder of Olipharma; and representatives from Olipharma's partner companies were also present at the opening ceremony.
Mr. Zhao Hai, founder and general manager of Olipharma, stated in his speech: "As a technical service company dedicated to the field of nucleic acid drugs, we feel deeply honored to be able to contribute to this industry. With the official opening of Olipharma's oligonucleotide drug CDMO platform, we have reached an important milestone."Subsequently, Mr. Zhao expressed heartfelt gratitude to the leaders at all levels, investors, team members, and partners for their care and support towards Olipharma.In the future, Olipharma will steadfastly build a high-standard nucleic acid drug production platform and system in China, better serve nucleic acid innovative drug companies, accelerate the research and development and production of nucleic acid drugs, contribute Chinese strength to the industry's development, and shoulder the mission of "making nucleic acid drugs benefit the world!"
Subsequently, Mr. Gu Hongjian, member of the Working Committee and Deputy Director of the Management Committee of Wu Zhong Economic Development Zone in Suzhou, delivered a speech. Director Gu extended his warm congratulations on the opening of Olipharma's Oligonucleotide Drug CDMO Platform.He pointed out that Wuzhong Economic Development Zone, as the main battleground and primary engine for Wuzhong's economic development, has already attracted more than 400 well-known enterprises, including Fortune 500 companies like Corning from the United States and GlaxoSmithKline, to settle down. It is gradually becoming a highland for biopharmaceutical innovation in the Yangtze River Delta region with a complete range of pharmaceutical categories and strong comprehensive R&D capabilities.Mr. Gu Hongjian mentioned that the technical team of Olipharma comes from one of the earliest groups in China to engage in the development of nucleic acid drug production processes and CMC research, with rich experience in project development and product registration. They have successively received honors such as the "Suzhou Innovative Small and Medium-sized Enterprise Title," "Arterial Network Future Healthcare 100 Strong," "2023 Annual Dongwu Innovation and Entrepreneurship Leading Talent," and "2023 Annual Gusu Innovation and Entrepreneurship Leading Talent." The successful establishment of Olipharma in Wuzhong Economic Development Zone will greatly promote the industrial clustering and industry development of nucleic acid drugs in Wuzhong District.He emphasized that Wu Zhong Economic Development Zone's development strategy of "strengthening the district through industry and leading through innovation" will continue to support the growth of enterprises within the zone. The zone is committed to providing the best services to businesses with dedication, passion, and effort, working hand-in-hand to create a bright future for Wu Zhong's biopharmaceuticals industry.
Mr. Li Jing, Vice President of Qingsong Capital, delivered a speech on behalf of the investors. He stated that nucleic acid drugs are currently a hot topic and frontier in the pharmaceutical field, possessing tremendous potential and broad application prospects. However, the development of the nucleic acid drug industry requires support from professional teams, capital, government departments, and individuals from all sectors of society. Olipharma, as a professional CDMO company for oligonucleotide drugs, will focus on helping clients address key aspects such as the scale-up of small nucleic acid drug production processes and CMC control. Qingsong Capital is a venture capital private equity investment firm focusing on biotechnology and healthcare, with a management team that has deep industry backgrounds in healthcare and extensive experience in private equity investment. On the occasion of this opening, let us wish Suzhou Olipharma Technology Co., Ltd. continued success and further important contributions to the development of nucleic acid drugs in China.
Suzhou Olipharma Technology Co., Ltd. is a professional pharmaceutical nucleic acid CDMO company that provides customers with "one-stop" services ranging from nucleic acid drug discovery, laboratory R&D, process and analytical development, CMC services, API production, to drug registration. The technical team of Olipharma comes from one of the earliest teams in China that started the development of nucleic acid drug manufacturing processes and CMC research, possessing extensive experience in project development and product registration. Currently, the company has established four leading core technology platforms in the industry: nucleic acid solid-phase synthesis, chemical modification and conjugation, process development and analysis, as well as CMC pharmaceutical research. It has also engaged in in-depth collaborations with multiple pharmaceutical companies and biotechnology firms both domestically and internationally.In 2023, the company's 3,000-square-meter GMP-compliant pilot platform officially began offering services, focusing on helping customers address critical challenges such as small nucleic acid drug process scale-up and CMC pharmaceutical research. The company will continue to provide compliant, high-quality, reliable, and efficient services to help customers enhance R&D efficiency, accelerate product registration and market entry, and jointly support the entire process of small nucleic acid drugs from preclinical to commercial production.Source of the Article: Olipharma
